Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases

JAMA. 2021 Sep 21;326(11):1068-1069. doi: 10.1001/jama.2021.11471.

Authors

Trond Trætteberg Serkland¹, Silje Skrede², Jon Andsnes Berg¹

Affiliations

¹ Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
² Haukeland University Hospital, University of Bergen, Bergen, Norway.

PMID: 34546308
DOI: 10.1001/jama.2021.11471

No abstract available

Publication types

Letter
Comment

MeSH terms

Crohn Disease* / drug therapy
Drug Monitoring*
Gastrointestinal Agents / therapeutic use
Humans
Infliximab / therapeutic use

Substances

Gastrointestinal Agents
Infliximab